CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 52 enrolled
Drug / intervention
LBH589 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00691938
NCT00691938Phase 2Completed
CompareCT.gov

A Phase I/II Study of LBH589 Plus Decitabine for Patients Age ≥ 60 Years With High Risk MDS or AML

Washington University School of Medicine·interventional·Posted Jun 6, 2008·Updated Oct 13, 2016

In Brief

A Phase 2 clinical trial evaluating LBH589 and Decitabine for Leukemia, Myeloid, Acute and Myelodysplastic Syndromes. Completed, enrolled 52 participants across 1 site.

Detailed Summary

This study is designed to evaluate the combination of LBH589 and decitabine in patients age ≥ 60 years with high risk Myelodysplastic Syndrome (IPSS Int-2 or High) or Acute Myeloid Leukemia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLeukemia, Myeloid, Acute, Myelodysplastic Syndromes
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 6, 2008
Enrollment StartJun 1, 2008
Primary CompletionJul 1, 2013
Study CompletionAug 1, 2014
TodayJul 2, 2026
Enrollment to primary: 5.1 yearsPosted 18.1 years ago

Interventions

LBH589drug

Decitabinedrug